<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807079</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000626790</org_study_id>
    <secondary_id>ARCAGY-GINECO-CE102</secondary_id>
    <secondary_id>ARCAGY-HYCAR</secondary_id>
    <secondary_id>INCA-RECF0757</secondary_id>
    <secondary_id>EUDRACT-2008-001842-19</secondary_id>
    <nct_id>NCT00807079</nct_id>
  </id_info>
  <brief_title>Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer</brief_title>
  <official_title>Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of topotecan when&#xD;
      given together with carboplatin and to see how well they work in treating patients with&#xD;
      relapsed or metastatic cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of topotecan hydrochloride when administered&#xD;
           with carboplatin in patients with relapsed or metastatic cervical cancer. (Phase I)&#xD;
&#xD;
        -  To determine the objective response rate in patients treated with this regimen. (Phase&#xD;
           II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the dose-limiting toxicities of this regimen in these patients. (Phase I)&#xD;
&#xD;
        -  To assess the progression-free survival of patients treated with this regimen. (Phase&#xD;
           II)&#xD;
&#xD;
        -  To assess the overall survival of patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  To assess the tolerability of this regimen in these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of topotecan hydrochloride&#xD;
      followed by a phase II study.&#xD;
&#xD;
      Patients receive oral topotecan hydrochloride on days 1, 8, and 15 and carboplatin IV on day&#xD;
      1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Patients complete a quality-of-life questionnaire at baseline and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of topotecan hydrochloride (Phase I)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (Phase II)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cervical cancer, including the following cell types:&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Adenosquamous cell carcinoma&#xD;
&#xD;
          -  Metastatic disease or in first relapse&#xD;
&#xD;
               -  Not curable by surgery and/or radiotherapy with or without chemotherapy&#xD;
&#xD;
          -  At least 1 non-irradiated measurable lesion&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Transaminases ≤ 3 times upper limit of normal (ULN) (≤ 5 times ULN in the presence of&#xD;
             liver metastases)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other cancer within the past 5 years except for adequately treated basal cell or&#xD;
             squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No swallowing disorders or gastrointestinal disease resulting in an inability to take&#xD;
             oral medication or a requirement for IV alimentation&#xD;
&#xD;
          -  No altered intestinal absorption&#xD;
&#xD;
          -  No peptic ulcers&#xD;
&#xD;
          -  No nephrostomy&#xD;
&#xD;
               -  Double-J catheter allowed&#xD;
&#xD;
          -  None of the following cardiovascular conditions within the past 6 months:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Coronary artery disease&#xD;
&#xD;
               -  NYHA class III or IV congestive heart failure&#xD;
&#xD;
               -  Ventricular arrhythmia&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  No infection or serious illness that would preclude study treatment&#xD;
&#xD;
          -  No contraindications to study treatment&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior cytotoxic therapy except for chemoradiotherapy or pelvic radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior platinum-based chemoradiotherapy&#xD;
&#xD;
          -  No concurrent participation in another clinical trial that could interfere with the&#xD;
             objectives of this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure Chauvenet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

